By Kelly Cloonan
Shares of BriaCell Therapeutics climbed after the company said its late stage breast cancer treatment outperformed leading antibody-drug conjugates for some patients in its Phase 2 study.
The stock rose 16% to $4.34 on Wednesday. Shares have declined 87% over the past 12 months.
The biotechnology company said its Bria-IMT plus check point inhibitors showed a 17.3-month survival rate for patients with hormone receptor-positive breast cancer, exceeding the 14.4 months of Trodelvy, the current ADC standard of care.
For patients with triple negative breast cancer, the survival data for the treatment was similar to that of Trodelvy but higher than that of chemotherapy, the company said.
Patients with hormone receptor-positive and triple negative breast cancer represent a significant proportion of the patient population, yet are the most difficult groups to treat, Chief Medical Officer Dr. Giuseppe Del Priore said.
The Phase 2 data shows Bria-IMT has the potential to provide an effective and well-tolerated therapeutic option for those patient groups, Del Priore said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 16, 2025 13:32 ET (17:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.